Cargando…

Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42

Well-differentiated papillary mesothelioma is an uncommon mesothelial neoplasm that most frequently arises in the peritoneal cavity of women of reproductive age. Whereas malignant mesothelioma is an aggressive tumor associated with poor outcome, well-differentiated papillary mesothelioma typically e...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevers, Meredith, Rabban, Joseph T., Garg, Karuna, Van Ziffle, Jessica, Onodera, Courtney, Grenert, James P., Yeh, Iwei, Bastian, Boris C., Zaloudek, Charles, Solomon, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309365/
https://www.ncbi.nlm.nih.gov/pubmed/30171198
http://dx.doi.org/10.1038/s41379-018-0127-2
_version_ 1783383364490756096
author Stevers, Meredith
Rabban, Joseph T.
Garg, Karuna
Van Ziffle, Jessica
Onodera, Courtney
Grenert, James P.
Yeh, Iwei
Bastian, Boris C.
Zaloudek, Charles
Solomon, David A.
author_facet Stevers, Meredith
Rabban, Joseph T.
Garg, Karuna
Van Ziffle, Jessica
Onodera, Courtney
Grenert, James P.
Yeh, Iwei
Bastian, Boris C.
Zaloudek, Charles
Solomon, David A.
author_sort Stevers, Meredith
collection PubMed
description Well-differentiated papillary mesothelioma is an uncommon mesothelial neoplasm that most frequently arises in the peritoneal cavity of women of reproductive age. Whereas malignant mesothelioma is an aggressive tumor associated with poor outcome, well-differentiated papillary mesothelioma typically exhibits indolent behavior. However, histologically differentiating between these two entities can be challenging, necessitating the development of distinguishing biomarkers. While the genetic alterations that drive malignant mesothelioma have recently been determined, the molecular pathogenesis of well-differentiated papillary mesothelioma is unknown. Here we performed genomic profiling on a cohort of ten well-differentiated papillary mesothelioma of the peritoneum. We identified that all tumors harbored somatic missense mutations in either the TRAF7 or CDC42 genes, and lacked alterations involving BAP1, NF2, CDKN2A, DDX3X, SETD2, and ALK that are frequent in malignant mesothelioma. We recently identified that another mesothelial neoplasm, adenomatoid tumor of the genital tract, is genetically defined by somatic missense mutations in the TRAF7 gene, indicating a shared molecular pathogenesis between well-differentiated papillary mesothelioma and adenomatoid tumors. To the best of our knowledge, well-differentiated papillary mesothelioma is the first human tumor type found to harbor recurrent mutations in the CDC42 gene, which encodes a Rho family GTPase. Immunohistochemistry demonstrated intact BAP1 expression in all cases of well-differentiated papillary mesothelioma, indicating that this is a reliable marker for distinguishing well-differentiated papillary mesothelioma from malignant mesotheliomas that frequently display loss of expression. Additionally, all well-differentiated papillary mesothelioma demonstrated robust expression of L1 cell adhesion molecule (L1CAM), a marker of NF-kB pathway activation, similar to that observed in adenomatoid tumors. In contrast, we have previously shown that L1CAM staining is not observed in normal mesothelial cells and malignant mesotheliomas of the peritoneum. Together, these studies demonstrate that well-differentiated papillary mesothelioma is genetically defined by mutually exclusive mutations in TRAF7 and CDC42 that molecularly distinguish this entity from malignant mesothelioma.
format Online
Article
Text
id pubmed-6309365
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-63093652019-02-28 Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42 Stevers, Meredith Rabban, Joseph T. Garg, Karuna Van Ziffle, Jessica Onodera, Courtney Grenert, James P. Yeh, Iwei Bastian, Boris C. Zaloudek, Charles Solomon, David A. Mod Pathol Article Well-differentiated papillary mesothelioma is an uncommon mesothelial neoplasm that most frequently arises in the peritoneal cavity of women of reproductive age. Whereas malignant mesothelioma is an aggressive tumor associated with poor outcome, well-differentiated papillary mesothelioma typically exhibits indolent behavior. However, histologically differentiating between these two entities can be challenging, necessitating the development of distinguishing biomarkers. While the genetic alterations that drive malignant mesothelioma have recently been determined, the molecular pathogenesis of well-differentiated papillary mesothelioma is unknown. Here we performed genomic profiling on a cohort of ten well-differentiated papillary mesothelioma of the peritoneum. We identified that all tumors harbored somatic missense mutations in either the TRAF7 or CDC42 genes, and lacked alterations involving BAP1, NF2, CDKN2A, DDX3X, SETD2, and ALK that are frequent in malignant mesothelioma. We recently identified that another mesothelial neoplasm, adenomatoid tumor of the genital tract, is genetically defined by somatic missense mutations in the TRAF7 gene, indicating a shared molecular pathogenesis between well-differentiated papillary mesothelioma and adenomatoid tumors. To the best of our knowledge, well-differentiated papillary mesothelioma is the first human tumor type found to harbor recurrent mutations in the CDC42 gene, which encodes a Rho family GTPase. Immunohistochemistry demonstrated intact BAP1 expression in all cases of well-differentiated papillary mesothelioma, indicating that this is a reliable marker for distinguishing well-differentiated papillary mesothelioma from malignant mesotheliomas that frequently display loss of expression. Additionally, all well-differentiated papillary mesothelioma demonstrated robust expression of L1 cell adhesion molecule (L1CAM), a marker of NF-kB pathway activation, similar to that observed in adenomatoid tumors. In contrast, we have previously shown that L1CAM staining is not observed in normal mesothelial cells and malignant mesotheliomas of the peritoneum. Together, these studies demonstrate that well-differentiated papillary mesothelioma is genetically defined by mutually exclusive mutations in TRAF7 and CDC42 that molecularly distinguish this entity from malignant mesothelioma. 2018-08-31 2019-01 /pmc/articles/PMC6309365/ /pubmed/30171198 http://dx.doi.org/10.1038/s41379-018-0127-2 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Stevers, Meredith
Rabban, Joseph T.
Garg, Karuna
Van Ziffle, Jessica
Onodera, Courtney
Grenert, James P.
Yeh, Iwei
Bastian, Boris C.
Zaloudek, Charles
Solomon, David A.
Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42
title Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42
title_full Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42
title_fullStr Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42
title_full_unstemmed Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42
title_short Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42
title_sort well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in traf7 and cdc42
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309365/
https://www.ncbi.nlm.nih.gov/pubmed/30171198
http://dx.doi.org/10.1038/s41379-018-0127-2
work_keys_str_mv AT steversmeredith welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42
AT rabbanjosepht welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42
AT gargkaruna welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42
AT vanzifflejessica welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42
AT onoderacourtney welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42
AT grenertjamesp welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42
AT yehiwei welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42
AT bastianborisc welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42
AT zaloudekcharles welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42
AT solomondavida welldifferentiatedpapillarymesotheliomaoftheperitoneumisgeneticallydefinedbymutuallyexclusivemutationsintraf7andcdc42